rs2280714 — IRF5 3'UTR

IRF5 rs2280714 — The 3' Expression Amplifier of the Interferon Risk Haplotype

Interferon Regulatory Factor 5 (IRF5) is a master transcription factor controlling the production of type I interferons (IFN-α and IFN-β) and pro-inflammatory cytokines including TNF-α, IL-6, and IL-12. The rs2280714 variant sits approximately 5 kb downstream of the IRF5 coding sequence in the 3' regulatory region. Although it is not the primary causal variant at this position, it is a reliable tag for the IRF5 risk haplotype¹¹ risk haplotype
A set of nearby variants that travel together through generations as a block; rs2280714-T marks one of three independent functional blocks in the IRF5 autoimmune risk haplotype and independently correlates with elevated IRF5 mRNA levels across multiple ancestral populations. Individuals carrying the T allele are more likely to have an immune system primed toward higher baseline interferon output — the same molecular signature underlying lupus, systemic sclerosis, and Sjögren syndrome susceptibility.

The Mechanism

The rs2280714 variant lies within the 3' regulatory region that controls IRF5 mRNA stability and polyadenylation site selection. Functional studies in lymphoblastoid cell lines from European, Han Chinese/Japanese, and Yoruba Nigerian individuals showed that the major T allele of rs2280714 correlates with a relative IRF5 expression ratio of 1.7-fold in Europeans²² major T allele of rs2280714 correlates with a relative IRF5 expression ratio of 1.7-fold in Europeans
Bonferroni-corrected p<0.0001 in CEU; p=0.001 in CHB+JPT; p=0.004 in YRI — consistent across three ancestral populations compared to individuals carrying the C allele, a pattern that was consistent across all three ancestral groups tested.

The closely linked variant rs10954213 (D'=1, r²=0.79 with rs2280714) is the primary functional element: its A allele creates a canonical AAUAAA polyadenylation signal that is disrupted by the G allele, causing mRNA cleavage and polyadenylation to shift to a more distal site. The shorter 3'-UTR transcript produced when the functional polyA site is used is more stable and more abundant³³ more stable and more abundant
The 3'-UTR length affects miRNA binding site accessibility and mRNA half-life; the shorter isoform escapes miRNA-mediated degradation and accumulates to higher levels. Because rs2280714-T tracks so closely with rs10954213-A in most haplotype blocks, the two variants show essentially interchangeable associations in most population studies. The key point is that carrying rs2280714-T means you very likely also carry the functional polyadenylation variant that elevates IRF5 expression.

The combined haplotype rs2004640-T / rs10954213-A / rs2280714-T produces a "double-hit" to IRF5 regulation: rs2004640 enables expression of an alternative exon 1B that generates more active IRF5 isoforms, while the polyadenylation variant (tagged by rs2280714) stabilizes those transcripts. Together they sustain higher baseline and inducible IRF5 activity — a lower immune threshold for triggering and maintaining the type I interferon cascade⁴⁴ lower immune threshold for triggering and maintaining the type I interferon cascade
The interferon cascade is normally self-limiting; these variants shift the setpoint so that the same immune stimulus produces a larger and more sustained response.

The Evidence

The clearest evidence comes from the UK SLE family study which found over-transmission of the rs2280714 T allele⁵⁵ found over-transmission of the rs2280714 T allele
GH-TDT P=0.007; FBAT P=0.015; transmission ratio 1:1.35 favoring T in affected offspring. The combined TAT haplotype (rs2004640-T / rs10954213-A / rs2280714-T) showed a dose-dependent relationship with IRF5 mRNA expression, confirming that allele count at this locus tracks linearly with output.

A Korean SLE replication study found that while rs2280714-T alone was not independently associated with SLE⁶⁶ found that while rs2280714-T alone was not independently associated with SLE
T allele frequency 0.395 in cases vs 0.402 in controls, OR=0.97, P=0.70, the two-marker haplotype rs2004640-T / rs2280714-T showed strong association (cases 0.380, controls 0.311, OR=1.36, P=9.64×10⁻⁵). Pooled across all ancestries, this haplotype reached P=2.11×10⁻¹⁶, establishing it as one of the most replicated autoimmune susceptibility signals in genetics. This pattern — weak independent signal but strong haplotype effect — is characteristic of secondary tag SNPs in tight LD with a functional variant, and is consistent with rs2280714's role as a proxy for rs10954213.

In systemic sclerosis, a Japanese study of 283 patients found that rs2280714 showed the strongest association among three IRF5 SNPs tested⁷⁷ the strongest association among three IRF5 SNPs tested
OR=1.42 (95% CI 1.15–1.75), P=0.0012, with preferential enrichment in diffuse cutaneous SSc and anti-topoisomerase I antibody-positive subsets — the disease subtypes with the most aggressive fibrotic and inflammatory features. This points to IRF5 as a driver of not just autoimmune susceptibility but also disease severity in SSc.

IRF5 mRNA expression has also been found elevated in NMOSD patients compared to controls in some cohorts, suggesting the interferon-amplifying haplotype may contribute to a broader class of autoimmune neuroinflammatory conditions. However, population-specific effects have been observed, and the rs2280714 variant alone shows inconsistent independent associations in NMOSD studies.

For rheumatoid arthritis, the evidence for rs2280714 as an independent risk factor is weak — the variant shows no significant association with RA across European cohorts — consistent with its role as a secondary tag rather than a primary functional variant for RA-specific disease pathways.

Practical Implications

Carrying the T allele, particularly one or two copies, means your IRF5 expression is likely modestly elevated at baseline compared to CC individuals. This does not predetermine autoimmune disease — the majority of T allele carriers remain healthy — but it means your type I interferon pathway operates closer to the threshold needed for chronic activation. Awareness is the main actionable output: recognizing early signs of IRF5-related autoimmune conditions enables earlier evaluation and intervention, which substantially improves long-term outcomes.

For most people with the CT genotype, no specialist referral is needed without symptoms. However, if other IRF5 risk variants (rs2004640-T or rs10488631-C) are also present, the combined haplotype risk is substantially higher, and proactive monitoring becomes more appropriate (those compound effects are captured by the haplotype analysis across all three IRF5 SNPs).

Interactions

The rs2280714-T allele is biologically meaningful primarily when co-inherited with rs2004640-T on the same chromosome (in cis), forming the risk haplotype. The combined haplotype (rs2004640-T / rs2280714-T) represents both altered splicing AND elevated transcript stability — a mechanistic synergy captured by the haplotype's pooled association of P=2.11×10⁻¹⁶ for SLE, far exceeding either variant's independent contribution.

rs2280714 is also part of the broader three-block IRF5 haplotype system alongside rs10488631 (3' downstream regulatory) and rs4728142 (promoter CGGGG indel). Individuals carrying risk alleles across all three blocks have the highest IRF5 expression and autoimmune risk. Additionally, the IRF5 risk haplotype interacts additively with STAT4 rs7574865, which amplifies cellular responsiveness to the interferons IRF5 drives — individuals with risk alleles at both loci can reach substantially amplified autoimmune risk up to OR=6.78 with five combined risk alleles in Sjögren's syndrome⁸⁸ up to OR=6.78 with five combined risk alleles in Sjögren's syndrome
Nordmark et al. Genes & Immunity 2009.